英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
dissertare查看　dissertare　在百度字典中的解释百度英翻中〔查看〕
dissertare查看　dissertare　在Google字典中的解释Google英翻中〔查看〕
dissertare查看　dissertare　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Shaping the Future of Oncology for Patients l Exelixis
    Exelixis is an oncology-focused biotech company innovating cancer treatments for life Find out how we're dedicated to giving more patients hope for the future
  • Cancer Clinical Trials and Pipeline l Exelixis
    * Sairopa B V (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805 ADC = antibody-drug conjugate; CRC = colorectal cancer; DLL3 = delta-like ligand 3; ILT2 = Ig-like transcript 2; IL13Rα2 = interleukin 13 receptor alpha 2; IND = investigational new drug application
  • Investors and News | Exelixis
    Exelixis is expanding its global innovation engine to evolve how cancer is treated and deliver for physicians, patients and partners
  • Our Medicines for Cancer Patients l Exelixis
    If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at medinfo@exelixis com or call 1-855-292-3935 (EXEL)
  • Building a Legacy of Oncology Excellence l Exelixis
    Exelixis extends its impact through strategic collaborations across drug discovery, development and commercialization, building on our long history of productive partnerships to move our molecules and business forward
  • Leadership Team l Exelixis
    One of Exelixis’ greatest strengths is its culture of focused execution We’re committed to moving quickly while turning over every stone to bring new standards of care to physicians and ultimately the cancer patients we serve
  • Innovating Oncology at the Speed of Experience l Exelixis
    Clinical trials and pipeline Pipeline expansion is a key driver of our growth strategy We continue to make significant progress across our internal discovery projects and collaborations to generate biotherapeutics, including antibody-drug conjugates and small molecules – with the goal of pursuing medical advances across a wide number of tumor types
  • Search Careers at Exelixis
    Qualified and interested candidates should apply to current openings on our Exelixis Careers website or on LinkedIn, Glassdoor and Indeed Exelixis accepts no responsibility for any costs or charges incurred as a result of fraudulent activity
  • Advancing Science for Cancer Treatments l Exelixis
    As we scale our business, pipeline and infrastructure to meet the challenges posed by cancer on a global scale, patients remain at the center of everything we do At Exelixis, the ultimate definition of success is our ability to help more patients living with cancer
  • Exelixis Announces U. S. FDA Approval of CABOMETYX® (cabozantinib) for . . .
    This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of CABOMETYX for patients with previously treated advanced neuroendocrine tumors; Exelixis’ ability or plans to immediately support these new indications; Exelixis’ commitment to improving the standard of





中文字典-英文字典  2005-2009